Table 2. Human cells and plasma levels... | American Society of Hematology

Table 2.

Human cells and plasma levels of HIV-1 p24 in peripheral blood of hu-PBL-NOD/SCID mice with HIVE

Treatment group, by week^*	Lymphocyte population, %					HIV-1 p24, mean pg/mL ± SEM
Treatment group, by week^*		CD3⁺	CD4⁺†	CD8⁺		HIV-1 p24, mean pg/mL ± SEM
Week 1
Control	33.33	16.22	14.97	5.26 ± 3.25
1-MT	46.36‡	19.56	22.25§	1.76 ± 0.66
Week 2
Control	51.76	20.38	26.91	198.0 ± 22.5
1-MT	39.80‡	17.92	19.63‡	103.0 ± 18.3∥
Week 3
Control	44.48	21.78	21.10	320.0 ± 48.3
1-MT	33.12	16.64	15.07	328.0 ± 63.22

Treatment group, by week^*	Lymphocyte population, %					HIV-1 p24, mean pg/mL ± SEM
Treatment group, by week^*		CD3⁺	CD4⁺†	CD8⁺		HIV-1 p24, mean pg/mL ± SEM
Week 1
Control	33.33	16.22	14.97	5.26 ± 3.25
1-MT	46.36‡	19.56	22.25§	1.76 ± 0.66
Week 2
Control	51.76	20.38	26.91	198.0 ± 22.5
1-MT	39.80‡	17.92	19.63‡	103.0 ± 18.3∥
Week 3
Control	44.48	21.78	21.10	320.0 ± 48.3
1-MT	33.12	16.64	15.07	328.0 ± 63.22

Days after MDM injection

No significant difference in percentage of CD4⁺ cells between the groups

P < .05, compared with control

P < .001, compared with control

P < .02, compared with control